Clinical Development Failure Risk: The failure of pipeline candidates (e.g., BCX9930) in clinical trials to demonstrate efficacy or safety could significantly impact future revenue streams and stock valuation.

Regulatory Approval Uncertainty Risk: Delays or outright rejection by regulatory bodies (like the FDA or EMA) for new drug applications or expanded indications could prevent market entry for promising therapies.

Commercial Performance of ORLADEYO Risk: The company's primary commercial product, ORLADEYO, may face challenges in achieving expected sales due to competitive pressures, market access issues, or physician and patient adoption rates.